Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Leukemia 1Kidney Neoplasms 1Hematologic Diseases 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1Blood Protein Disorders 1

Interventions

Dexamethasone 10Bortezomib 7Lenalidomide 4isatuximab 3Calcium Dobesilate 3pomalidomide 2Thalidomide 2Gemcitabine 2Cyclophosphamide 2vinflunine 1melflufen 1glucarpidase 1gallium 68 PSMA-11 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Tablets 1Ranitidine 1Pluvicto 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Eplerenone 1Doxorubicin 1Diphenhydramine 1Carboplatin 1Bendamustine Hydrochloride 1BHQ880 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency × Ranitidine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡